Public health genomics

Lokavant Expands Team to Drive Strategic Direction of AI-Based Clinical Trial Feasibility Solution

Retrieved on: 
Mardi, mai 7, 2024
Technology, Clinical Trials, Professional Services, Biotechnology, Health, Data Analytics, Other Science, Science, Artificial Intelligence, University, Sonata, Public health, Drug development, AI, Microsoft Excel, GSK plc, Advisory board, Doctor of Philosophy, Pharmacy, Artificial intelligence, Data science, ChromeOS, Data, Patient, RWD, Noise, Medicine, Bristol Myers Squibb, Public health genomics, Clinical trial, Genomics, Therapy, Roivant Sciences, Pharmaceutical industry

The Lokavant Advisory Board brings together accomplished leaders in pharmaceutical research and development who are experts in global clinical trial operations.

Key Points: 
  • The Lokavant Advisory Board brings together accomplished leaders in pharmaceutical research and development who are experts in global clinical trial operations.
  • They work closely with the Lokavant leadership team, providing valuable insights into drivers for the evolving data and analytics needs of clinical trial sponsors and contract research organizations (CROs).
  • “I’m excited to work with Aaron and the new advisory team to incorporate their learnings into our clinical trial intelligence platform and study feasibility applications.
  • Together, we can drive efficiencies in trial operations while accelerating clinical research.”

Windtree Announces Publication on its SERCA2a Activator Drug Candidate for Chronic and Acute Heart Failure

Retrieved on: 
Mardi, février 28, 2023
Windtree Therapeutics, Metabolite, Therapy, Arrhythmia, Journal of Pharmacology and Experimental Therapeutics, CMO, Istaroxime, Acute decompensated heart failure, Treatment, Journal, Heart failure, Probability, Activity, Relaxation, Human, Calcium, Public health genomics, Cardiogenic shock, Experiment, Pharmaceutical industry, Medical device, Pharmacology

The publication emphasizes the interest in SERCA2a as a target in treating heart failure because it is instrumental in calcium management, critically important in heart muscle contraction and relaxation.

Key Points: 
  • The publication emphasizes the interest in SERCA2a as a target in treating heart failure because it is instrumental in calcium management, critically important in heart muscle contraction and relaxation.
  • Our SERCA2a activators uniquely interfere with phospholamban, a protein that inhibits SERCA2a function and does so excessively in heart failure.
  • The preclinical data discussed in the paper provides rationale for selective targeting of SERCA2A in the treatment of heart failure.
  • “Windtree’s SERCA2a activator drug candidates could represent a promising IV or oral approach to treat heart failure,” said Steve Simonson, CMO of Windtree Therapeutics.

MyAfroDNA, a Newly Established African-centric Biobank that Aims to Diversify Translational and Genomics Research Begins Operation

Retrieved on: 
Mardi, octobre 25, 2022
Genomics, American Association of Public Health Physicians, Research, Biobank, Biomedical Research, Public health genomics, Health, Public health, Collection, Global health, Pharmaceutical industry, Southern Nigeria

The African-centric biobank offers access to ethically sourced African biospecimens across several therapeutic areas for researchers interested in leveraging from such African bioresources to diversify and advance their research efforts.

Key Points: 
  • The African-centric biobank offers access to ethically sourced African biospecimens across several therapeutic areas for researchers interested in leveraging from such African bioresources to diversify and advance their research efforts.
  • Dr. Justin Eze Ideozu, the founder of MyAfroDNA states, "the biobank has a vision to ensure people of African ancestry benefit from advances in translational and genomics research.
  • Dr. Siyeofori Dede, a Public Health Physician with a predilection for Public Health Genomics, is a Co-Principal Investigator of the Biobank.
  • The company is open to collaborate with researchers from for-profit and non-profit institutions, including direct-to-consumer companies, biobanks, academic institutions, research institutions, health institutions, and individuals.